Patricia Greninger

15.4k citations

33 papers · 5.2k indexed · 3 hit papers · h-index 21

Molecular Biology top 2%
Oncology top 2%
Cancer Research top 1%
Pulmonary and Respiratory Medicine top 1%
Computational Theory and Mathematics top 1%

Co-authors: Cyril H. Benes Ultan McDermott Daniel A. Haber Mathew J. Garnett Elena J. Edelman Jorge Soares P. Andrew Futreal Simon Forbes
Topics: Protein Degradation and Inhibitors (7 papers)Neuroblastoma Research and Treatments (6 papers)Lung Cancer Treatments and Mutations (6 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Science Cell Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom Germany

In The Last Decade

Patricia Greninger

32 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

2012 2.6k citations Wanjuan Yang, Jorge Soares et al. Nucleic Acids Research profile →
A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

2009 630 citations Anurag Singh, Patricia Greninger et al. Cancer Cell profile →
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Patricia Greninger

Since Specialization

Citations

This map shows the geographic impact of Patricia Greninger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Greninger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Greninger more than expected).

Fields of papers citing papers by Patricia Greninger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Greninger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Greninger. The network helps show where Patricia Greninger may publish in the future.

Co-authorship network of co-authors of Patricia Greninger

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Greninger. A scholar is included among the top collaborators of Patricia Greninger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Greninger. Patricia Greninger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells 2022 ·Nature Communications ·Yang Sun,Lu Hu,Zhipeng Tao,Gopala K. Jarugumilli,(unknown),Alka Singh,Qi Li,Jennifer L. Cotton,Patricia Greninger,Regina K. Egan,Y. Tony Ip,Cyril H. Benes,Jianwei Che,Junhao Mao,Xu Wu	70
2	High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition 2022 ·Cell Reports ·Jinyang Cai,Sheeba Jacob,Richard Kurupi,(unknown),(unknown),Patricia Greninger,Regina K. Egan,Giovanna T. Stein,Ellen Murchie,Joseph McClanaghan,Yuta Adachi,(unknown),Mikhail G. Dozmorov,John Glod,Sosipatros A. Boikos,Hiromichi Ebi,Huai-Xiang Hao,Giordano Caponigro,Cyril H. Benes,Anthony C. Faber	10
3	Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma 2021 ·Molecular Cancer Therapeutics ·(unknown),Kateryna Krytska,Timothy L. Lochmann,Renata Sano,(unknown),(unknown),Qasim A. Khan,(unknown),(unknown),Jinyang Cai,Sheeba Jacob,Richard Kurupi,Bin Hu,Mikhail G. Dozmorov,Patricia Greninger,Andrew J. Souers,Cyril H. Benes,Yaël P. Mossé,Anthony C. Faber	13
4	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors 2018 ·Cancer Research ·(unknown),Marta Baro,(unknown),Azeet Narayan,Wei Cui,Patricia Greninger,Regina K. Egan,Abhijit A. Patel,Cyril H. Benes,W. Mark Saltzman,Joseph N. Contessa	55
5	Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity 2018 ·Clinical Cancer Research ·(unknown),Joseph Tillotson,Alison Yeomans,(unknown),(unknown),Carlos Jiménez‐Romero,(unknown),Lingxiao Li,Amit Dipak Amin,(unknown),(unknown),Andrew J. Ambrose,Gillian Paine-Murrieta,Patricia Greninger,Francisco Vega,Cyril H. Benes,Graham Packham,Abimael D. Rodrı́guez,Eli Chapman,Jonathan H. Schatz	36
6	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression 2017 ·Clinical Cancer Research ·Timothy L. Lochmann,Konstantinos V. Floros,Mitra Naseri,Krista M. Powell,(unknown),Ryan J. March,Giovanna T. Stein,Patricia Greninger,(unknown),Laura R. Saunders,Scott J. Dylla,Carlotta Costa,Sosipatros A. Boikos,Joel Johansson,Andrew J. Souers,Geoffrey W. Krystal,Hisashi Harada,Cyril H. Benes,Anthony C. Faber	93
7	Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics 2017 ·Molecular Cancer Therapeutics ·S.W. Ember,Que T. Lambert,Norbert Berndt,Steven Gunawan,Muhammad Ayaz,Marilena Tauro,J. Zhu,Paula J. Cranfill,Patricia Greninger,Conor C. Lynch,Cyril H. Benes,Harshani R. Lawrence,Gary W. Reuther,Nicholas J. Lawrence,E. Schönbrunn	41
8	Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities 2017 ·Nature Biotechnology ·John D. Lapek,Patricia Greninger,Robert Morris,Arnaud Amzallag,Iulian Pruteanu-Malinici,Cyril H. Benes,Wilhelm Haas	104
9	Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response 2016 ·Cancer Research ·Andrew R. Conery,Richard C. Centore,(unknown),(unknown),Archana Bommi‐Reddy,Charlie Hatton,Barbara M. Bryant,Patricia Greninger,Arnaud Amzallag,Cyril H. Benes,Jennifer A. Mertz,Robert J. Sims	23
10	A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors 2015 ·Cancer Discovery ·Capucine Van Rechem,Joshua C. Black,Patricia Greninger,(unknown),Carlos Donado,(unknown),Brendon Ladd,David C. Christiani,Cyril H. Benes,Johnathan R. Whetstine	22
11	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation 2014 ·Cancer Research ·Meng Wang,(unknown),(unknown),Patricia Greninger,Anurag Singh,Yunfeng Pan,Dipanjan Chowdhury,Mechthild Krause,Michaël Baumann,Cyril H. Benes,Jason A. Efstathiou,Jeff Settleman,Henning Willers	55
12	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibitionbreakdown → 2013 ·Cancer Discovery ·Alexandre Puissant,Stacey M. Frumm,Gabriela Alexe,Christopher F. Bassil,Jun Qi,Yvan H. Chanthery,Erin A. Nekritz,Rhamy Zeid,W. Clay Gustafson,Patricia Greninger,Matthew J. Garnett,Ultan McDermott,Cyril H. Benes,Andrew L. Kung,William A. Weiss,James E. Bradner,Kimberly Stegmaier	457
13	EGFR-Activating Mutations Correlate with a Fanconi Anemia–like Cellular Phenotype That Includes PARP Inhibitor Sensitivity 2013 ·Cancer Research ·(unknown),Meng Wang,Liliana Gheorghiu,(unknown),Patricia Greninger,Kerstin Borgmann,Jeffrey Settleman,Cyril H. Benes,Lecia V. Sequist,Lee Zou,Henning Willers	35
14	Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma 2012 ·Cancer Discovery ·Lei He,Kristine Torres‐Lockhart,Nicole Forster,Saranya Ramakrishnan,Patricia Greninger,Mathew J. Garnett,Ultan McDermott,S. Michael Rothenberg,Cyril H. Benes,Leif W. Ellisen	54
15	Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsbreakdown → 2012 ·Nucleic Acids Research ·Wanjuan Yang,Jorge Soares,Patricia Greninger,Elena J. Edelman,Howard Lightfoot,Simon Forbes,Nidhi Bindal,(unknown),James Smith,I. Richard Thompson,Sridhar Ramaswamy,P. Andrew Futreal,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Ultan McDermott,Mathew J. Garnett	2597
16	TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers 2012 ·Cell ·Anurag Singh,Michael F. Sweeney,Min Yu,Alexa Burger,Patricia Greninger,Cyril H. Benes,Daniel A. Haber,Jeff Settleman	222
17	Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors 2009 ·Cancer Research ·Ultan McDermott,(unknown),A. John Iafrate,Shyamala Maheswaran,Hannah Stubbs,Patricia Greninger,(unknown),Randy Milano,Angela Tam,Diana Lee,(unknown),Brian W. Brannigan,Lindsey E. Ulkus,Xiaojun Ma,Mark G. Erlander,Daniel A. Haber,Sreenath V. Sharma,Jeffrey Settleman	83
18	Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe 2009 ·Clinical Cancer Research ·Fabrizio Galimberti,(unknown),Xi Liu,Hua Li,Vincent A. Memoli,Simon R. Green,James DiRenzo,Patricia Greninger,Sreenath V. Sharma,Jeff Settleman,Duane A. Compton,Ethan Dmitrovsky	60
19	A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survivalbreakdown → 2009 ·Cancer Cell ·Anurag Singh,Patricia Greninger,Daniel R. Rhodes,Louise A. Koopman,(unknown),Nabeel Bardeesy,Jeff Settleman	630
20	Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors 2008 ·Cancer Research ·Ultan McDermott,A. John Iafrate,Nathanael S. Gray,Toshi Shioda,Marie Classon,Shyamala Maheswaran,Wenjun Zhou,Hwan Geun Choi,Shannon L. Smith,Lori Dowell,Lindsey E. Ulkus,Georgiana Kuhlmann,Patricia Greninger,James G. Christensen,Daniel A. Haber,Jeffrey Settleman	312

About Patricia Greninger

Patricia Greninger is a scholar working on Oncology, Cancer Research and Neurology, having authored 33 papers that have together received 5.2k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (7 papers), Neuroblastoma Research and Treatments (6 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Cancer Research (1.4k citations), Oncology (1.6k citations) and Molecular Biology (3.7k citations). Patricia Greninger has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Cyril H. Benes, Ultan McDermott, Daniel A. Haber, Mathew J. Garnett, Elena J. Edelman, Jorge Soares, P. Andrew Futreal, Simon Forbes, Sridhar Ramaswamy and Nidhi Bindal. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact